BeOne Medicines Ltd. American Depositary Shares

Day range

$370.75 – $377.16

Open

$374.14

Prev close

$377.63

Volume

259.45K

Market cap

$42.72B

Shares out

109.79M

P/E

65.15

P/S

6.97

P/B

8.26

P/FCF

33.65

ROE

12.7%

ROA

7.1%

Debt/Equity

0.21

Div yield

0.00%

As of Oct 23, 2026

• Share repurchase programJun 11, 2026

  Proposal, within the parameters of the HK Listing Rules, to approve the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such resolution up to the next annual general meeting of shareholders of the Company.

• Regulatory decisionMay 15, 2026

  BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.

• Debt retirementDec 19, 2025

  On December 16, 2025, the Company utilized a portion of the proceeds from borrowings under the Facilities Agreement to repay in full all outstanding amounts owed under the Company's Facility Agreement, dated as of December 9, 2024, by and between the Company and China Merchants Bank Co., Ltd. (the 'CMB Credit Facility'), and terminated all commitments by the lender to extend further credit under the CMB Credit Facility.

• Executive officer appointmentDec 18, 2025

  On December 17, 2025, BeOne Medicines Ltd. (the "Company") appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company. In this role, Dr. Wang will oversee the research and development functions as well as other functions, including business development and alliance management.

• Guarantee or letter of creditNov 19, 2025

  Except as otherwise provided by applicable law, all obligations under the Loan Facilities are unconditionally guaranteed jointly and severally, by the Guarantors. The Loan Facilities are secured on a first priority basis by a security interest in the equity interests of a member of the Group and security interests in, and mortgage on, the Company's manufacturing and clinical R&D facility in New Jersey.

Days to cover

5.0

Short interest

1.93M

Avg volume

389.45K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
  positiveZacks Investment Research· Oct 15, 2026
• JAZZ Rises on Updated OS Results From Gastric Cancer Study
  positiveZacks Investment Research· Sep 1, 2026
• Zymeworks Announces Participation in Upcoming Investor Conferences
  neutralGlobeNewswire Inc.· May 13, 2026
• Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
  neutralGlobeNewswire Inc.· Mar 23, 2026
• Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
  neutralGlobeNewswire Inc.· Feb 12, 2026